You are here

drug pricing

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Stat

Alzheimer's disease

Flag link:

Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper

Aligning drug prices with ICER estimates could save tens of billions of dollars — JAMA paper

Endpoints

Inflation Reduction Act

Flag link:

Pfizer's plan for $110+ Covid-19 vaccines riles up US senators

Pfizer's plan for $110+ Covid-19 vaccines riles up US senators

Endpoints

Flag link:

On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega

On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega

Fierce Pharma

Flag link:

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Forbes

Flag link:

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

A $3.5M ‘bargain’? CSL’s hemophilia B drug sets new pricing benchmark, as gene therapy costs mount

Medical Marketing and Media

Flag link:

Sanders poised to lead Senate health committee

Sanders poised to lead Senate health committee

BioPharma Dive

Flag link:

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

Fierce Pharma

Flag link:

Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA

Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA

BioSpace

Inflation Reduction Act

Flag link:

Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Alnylam scraps trial in rare eye disorder, blaming drug price reforms

Pharmaphorum

Stargardt disease

Inflation Reduction Act

Flag link:

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

ICER on MS drugs: TG's ublituximab not cost effective at the same price as Roche's ocrelizimab

Endpoints

multiple sclerosis

TG Therapeutics

Flag link:

President Biden offers another push on drug price savings via executive order

President Biden offers another push on drug price savings via executive order

Endpoints

Flag link:

Big Pharma Says Drug Prices Reflect R&D Cos, but new study finds no correlation between research and development spending and outlandish drug prices

Big Pharma Says Drug Prices Reflect R&D Cos, but new study finds no correlation between research and development spending and outlandish drug prices

Wired

Flag link:

ALS drug's approval draws cheers from patients, questions from skeptics

ALS drug's approval draws cheers from patients, questions from skeptics

NPR

Amylyx Pharmaceuticals

Flag link:

New drug price law could help Part D enrollees who can't fill cancer treatments due to costs, White House says

New drug price law could help Part D enrollees who can't fill cancer treatments due to costs, White House says

Endpoints

Medicare Part D

Inflation Reduction Act

Flag link:

Novo Nordisk, Gilead, BMS and AstraZeneca will feel the most pain from Biden's pricing bill: analysts

Novo Nordisk, Gilead, BMS and AstraZeneca will feel the most pain from Biden's pricing bill: analysts

Fierce Pharma

Inflation Reduction Act

Gilead Sciences

Bristol Myers Squibb

Flag link:

AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

Morningstar

Flag link:

New study reveals the extent to which drugmakers use condition-specific charities to induce spending on costly drugs

New study reveals the extent to which drugmakers use condition-specific charities to induce spending on costly drugs

Endpoints

Flag link:

What “Negotiating” With Medicare Means For Drug Makers: A Mixture Of Price Controls And Actual Negotiations

What “Negotiating” With Medicare Means For Drug Makers: A Mixture Of Price Controls And Actual Negotiations

Forbes

Inflation Reduction Act

Flag link:

Patient groups sue feds to crack down on insurer, PBM copay adjustment programs

Patient groups sue feds to crack down on insurer, PBM copay adjustment programs

Fierce Healthcare

copay asssistance programs

Flag link:

Pages